Momelotinib is a highly potent inhibitor of FLT3-mutant AML
M. Azhar, Z. Kincaid, M. Kesarwani, T. Latif, D. Starczynowski, M. Azam
This study shows momelotinib is a potent FLT3 inhibitor effective against FLT3-mutant AML, including resistant variants, and suppresses resistance mechanisms like FLT3 ligand and cytokine signaling.
bioRxiv · Mar 18, 2021Cancer Biology